Maryland-based biotech Intrexon Corp. inked an early research collaboration with Janssen Pharmaceutica NV to develop treatments for type 2 diabetes and other metabolic disorders, including obesity.
The deal was brokered by the big pharma's recently established business development engine Johnson & Johnson Innovation. The Centers of...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
